Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07152223
NA

Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases

Sponsor: Guangzhou Bio-gene Technology Co., Ltd

View on ClinicalTrials.gov

Summary

This study is a single-arm, single-center Investigator-Initiated Trial (IIT) designed to evaluate the safety, pharmacokinetic profile, and preliminary efficacy of CD19-BCMA CAR-T cells in subjects diagnosed with connective tissue diseases.

Official title: A Single-center Clinical Study to Evaluate the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases

Key Details

Gender

All

Age Range

1 Year - 70 Years

Study Type

INTERVENTIONAL

Enrollment

20

Start Date

2025-08-30

Completion Date

2029-08-31

Last Updated

2025-09-03

Healthy Volunteers

No

Interventions

BIOLOGICAL

CAR-T

Eligible subjects who successfully passed screening will receive CAR-T cell infusion on Day 0 after lymphodepleting preconditioning chemotherapy.

Locations (1)

Dongguan Taixin Hospital

Dongguan, Guangdong, China